Phase 2a, multicenter, parallel group, placebo-controlled, double-blind, randomized study to investigate the efficacy and safety of tezepelumab in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) (COURSE)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ASTRAZENECA AB
- Phase: II
- Execution start: 17/06/2022
- End of execution: 30/03/2024
- PI: BERNARDINO ALCAZAR NAVARRETE